Close

Xencor (XNCR) Doses First Patient in Phase 1b Trial of Subcutaneous Formulation of XmAb7195

Go back to Xencor (XNCR) Doses First Patient in Phase 1b Trial of Subcutaneous Formulation of XmAb7195